Second Primary Malignancy After Radioiodine Therapy in Thyroid Cancer Patient: A Nationwide Study

CONCLUSION: Total cumulative doses of 100 mCi or less of RAI can be safely administered without concerns about second primary malignancy. However, the risk of second primary malignancy increases in a dose-dependent manner, and the risk-benefit needs to be considered for doses over 100 mCi of RAI therapy.PMID:37982105 | PMC:PMC10654320 | DOI:10.1007/s13139-023-00818-1

Source: Molecular Medicine - November 20, 2023 Category: Molecular Biology Authors: Chae Moon Hong Junik Son Min Kyung Hyun Jang Won Lee Jaetae Lee Source Type: research